AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines
- PMID: 19064730
- DOI: 10.1182/blood-2008-02-137737
AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines
Abstract
The PI3K/AKT signaling is activated in various hematologic malignancies. We evaluated the effect of a novel, pan-AKT kinase inhibitor, GSK690693, on the proliferation of 112 cell lines representing different hematologic neoplasia. Fifty-five percent of all cell lines tested were sensitive to AKT inhibitor (EC(50)<1 microM), with acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, and Burkitt lymphoma showing 89%, 73%, and 67% sensitivity to GSK690693, respectively. The antiproliferative effect was selective for the malignant cells, as GSK690693 did not inhibit the proliferation of normal human CD4(+) peripheral T lymphocytes as well as mouse thymocytes. Phosphorylation of downstream substrates of AKT was reduced in both sensitive and insensitive cell lines on treatment with GSK690693, suggesting that the cause of resistance was not related to the lack of AKT kinase inhibition. Consistent with the role of AKT in cell survival, GSK690693 also induced apoptosis in sensitive ALL cell lines. Overall, our data provide direct evidence for the role of AKT signaling in various hematologic malignancies, especially ALL and some lymphomas.
Similar articles
-
Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693.BMC Genomics. 2010 Jul 6;11:419. doi: 10.1186/1471-2164-11-419. BMC Genomics. 2010. PMID: 20604938 Free PMC article.
-
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.Oncotarget. 2015 Mar 30;6(9):6597-610. doi: 10.18632/oncotarget.3260. Oncotarget. 2015. PMID: 25788264 Free PMC article.
-
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.Cancer Res. 2008 Apr 1;68(7):2366-74. doi: 10.1158/0008-5472.CAN-07-5783. Cancer Res. 2008. PMID: 18381444
-
New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.Cell Signal. 2014 Jan;26(1):149-61. doi: 10.1016/j.cellsig.2013.09.021. Epub 2013 Oct 16. Cell Signal. 2014. PMID: 24140475 Review.
-
Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.J Cell Physiol. 2018 Oct;233(10):6440-6454. doi: 10.1002/jcp.26539. Epub 2018 Apr 18. J Cell Physiol. 2018. PMID: 29667769 Review.
Cited by
-
EGCG protects the mouse brain against cerebral ischemia/reperfusion injury by suppressing autophagy via the AKT/AMPK/mTOR phosphorylation pathway.Front Pharmacol. 2022 Sep 6;13:921394. doi: 10.3389/fphar.2022.921394. eCollection 2022. Front Pharmacol. 2022. PMID: 36147330 Free PMC article.
-
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Oncotarget. 2011 Mar;2(3):135-64. doi: 10.18632/oncotarget.240. Oncotarget. 2011. PMID: 21411864 Free PMC article. Review.
-
Leptin activates Akt in oesophageal cancer cells via multiple atorvastatin-sensitive small GTPases.Mol Cell Biochem. 2021 Jun;476(6):2307-2316. doi: 10.1007/s11010-021-04067-8. Epub 2021 Feb 13. Mol Cell Biochem. 2021. PMID: 33582946 Free PMC article.
-
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Mol Cell Ther. 2015 Mar 20;3:2. doi: 10.1186/s40591-015-0040-8. eCollection 2015. Mol Cell Ther. 2015. PMID: 26056603 Free PMC article.
-
The future of small molecule inhibitors in lymphoma.Curr Oncol Rep. 2009 Sep;11(5):378-85. doi: 10.1007/s11912-009-0051-1. Curr Oncol Rep. 2009. PMID: 19679013 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials